STZ induced diabetes and also lead to dyslipidemia. Oral administration of CS seed extracts significantly lowered total cholesterol (TC), LDLHDL ratio, TCHDL ratio, thus, reducing the cardiovascular risk. HDL levels were slightly increased with CS seed extract compared to diabetic control group but not statistically significant. There was also statistically insignificant reduction in the atherogenic index with CS seed extract compared to diabetic control.
Conclusions:
CS seed extract (40 mg/kg) orally may have considerable therapeutic benefit as a hypolipidemic agent and can be suggested as a potential dietary add on.